Potential of Gamma/delta T Cells for Solid Tumor Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 10

PMID 39253082

Authors

Dantong Zhu

Xijing Ren

Wanting Xie

Jianjun Chen

Shiying Liang

Mingzhe Jiang

Junyi Wang

Zhendong Zheng

Affiliations

Soon will be listed here.

Abstract

Gamma/delta T (γδ T)cells possess a unique mechanism for killing tumors, making them highly promising and distinguished among various cell therapies for tumor treatment. This review focuses on the major histocompatibility complex (MHC)-independent recognition of antigens and the interaction between γδ T cells and solid tumor cells. A comprehensive review is provided regarding the classification of human gamma-delta T cell subtypes, the characteristics and mechanisms underlying their functions, as well as their r545egulatory effects on tumor cells. The involvement of γδ T cells in tumorigenesis and migration was also investigated, encompassing potential therapeutic targets such as apoptosis-related molecules, the TNF receptor superfamily member 6(FAS)/FAS Ligand (FASL) pathways, butyrophilin 3A-butyrophilin 2A1 (BTN3A-BTN2A1) complexes, and interactions with CD4, CD8, and natural killer (NK) cells. Additionally, immune checkpoint inhibitors such as programmed cell death protein 1/Programmed cell death 1 ligand 1 (PD-1/PD-L1) have the potential to augment the cytotoxicity of γδ T cells. Moreover, a review on gamma-delta T cell therapy products and their corresponding clinical trials reveals that chimeric antigen receptor (CAR) gamma-delta T therapy holds promise as an approach with encouraging preclinical outcomes. However, practical issues pertaining to manufacturing and clinical aspects need resolution, and further research is required to investigate the long-term clinical side effects of CAR T cells. In conclusion, more comprehensive studies are necessary to establish standardized treatment protocols aimed at enhancing the quality of life and survival rates among tumor patients utilizing γδ T cell immunotherapy.

References

Papadopoulou M, Tieppo P, McGovern N, Gosselin F, Chan J, Goetgeluk G . TCR Sequencing Reveals the Distinct Development of Fetal and Adult Human Vγ9Vδ2 T Cells. J Immunol. 2019; 203(6):1468-1479. DOI: 10.4049/jimmunol.1900592. View

Cui X, Xu Z, Zhao Z, Sui D, Ren X, Huang Q . Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma. Int J Biol Sci. 2013; 9(2):134-41. PMC: 3572395. DOI: 10.7150/ijbs.4891. View

Bretthauer M, Loberg M, Wieszczy P, Kalager M, Emilsson L, Garborg K . Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. N Engl J Med. 2022; 387(17):1547-1556. DOI: 10.1056/NEJMoa2208375. View

Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I . Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19(12):1617-1629. DOI: 10.1016/S1470-2045(18)30578-3. View

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

Zakeri N, Hall A, Swadling L, Pallett L, Schmidt N, Diniz M . Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat Commun. 2022; 13(1):1372. PMC: 8927126. DOI: 10.1038/s41467-022-29012-1. View

Chen H, Joalland N, Bridgeman J, Alchami F, Jarry U, Khan M . Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8 T cells. Immunol Cell Biol. 2017; 95(7):620-629. PMC: 5550559. DOI: 10.1038/icb.2017.21. View

Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K . Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol. 2010; 40(7):1927-37. DOI: 10.1002/eji.200940157. View

Correia D, Fogli M, Hudspeth K, Gomes Da Silva M, Mavilio D, Silva-Santos B . Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood. 2011; 118(4):992-1001. DOI: 10.1182/blood-2011-02-339135. View

10.

Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier J, Scotet E . V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol. 2005; 175(8):5481-8. DOI: 10.4049/jimmunol.175.8.5481. View

11.

Valle J, Vogel A, Denlinger C, He A, Bai L, Orlova R . Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. 2021; 22(10):1468-1482. DOI: 10.1016/S1470-2045(21)00409-5. View

12.

Zhu R, Yan Q, Wang Y, Wang K . Biological characteristics of γδT cells and application in tumor immunotherapy. Front Genet. 2023; 13:1077419. PMC: 9846053. DOI: 10.3389/fgene.2022.1077419. View

13.

Huang S, Pan C, Lin Y, Chen M, Chen Y, Jan C . BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors. Adv Sci (Weinh). 2023; 10(17):e2206856. PMC: 10265101. DOI: 10.1002/advs.202206856. View

14.

Kabelitz D, Hinz T, Dobmeyer T, Mentzel U, Marx S, Bohme A . Clonal expansion of Vgamma3/Vdelta3-expressing gammadelta T cells in an HIV-1/2-negative patient with CD4 T-cell deficiency. Br J Haematol. 1997; 96(2):266-71. DOI: 10.1046/j.1365-2141.1997.d01-2027.x. View

15.

Perriman L, Tavakolinia N, Jalali S, Li S, Hickey P, Amann-Zalcenstein D . A three-stage developmental pathway for human Vγ9Vδ2 T cells within the postnatal thymus. Sci Immunol. 2023; 8(85):eabo4365. DOI: 10.1126/sciimmunol.abo4365. View

16.

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

17.

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View

18.

Guo L, Shi G, Gao Z, Shen J, Xing R, Qian Z . Response to hepatocarcinoma Hca-F of mice immunized with heat shock protein 70 from elemene combo tumor cell vaccine. Cell Mol Immunol. 2006; 3(4):291-5. View

19.

Fournie J, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F . What lessons can be learned from γδ T cell-based cancer immunotherapy trials?. Cell Mol Immunol. 2012; 10(1):35-41. PMC: 4003170. DOI: 10.1038/cmi.2012.39. View

20.

Castella B, Foglietta M, Riganti C, Massaia M . Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. Front Immunol. 2018; 9:1492. PMC: 6036291. DOI: 10.3389/fimmu.2018.01492. View